PACAP-38 Protocol: Complete Cycling & Dosing Guide

PACAP-38 Protocol: Complete Cycling & Dosing Guide

DISCLAIMER: This guide is educational content for research purposes only. PACAP-38 is an experimental peptide with no approved therapeutic indications. It is not approved for human use by regulatory agencies. This content is not medical advice. Consult with a qualified healthcare provider before using any research peptides. Users assume all risks associated with administration. Individual responses vary significantly.

Overview

PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide-38) is a 38-amino acid neuropeptide with pleiotropic effects across the nervous, endocrine, and immune systems. Its primary appeal in research and performance contexts stems from neuroprotective properties, stress response modulation, and theoretical support for metabolic, cognitive, and recovery-related outcomes.

Key Pharmacological Reality: PACAP-38 operates through three G-protein coupled receptors (PAC1, VPAC1, VPAC2), triggering robust cAMP elevation and downstream PKA/MAPK signaling. At PAC1 receptors specifically, it also activates phospholipase C, mobilizing intracellular calcium. This dual signaling cascade produces potent effects on neuronal survival, BDNF upregulation, HPA axis modulation, and catecholamine release—but also consistent cardiovascular side effects (flushing, hypotension, tachycardia).

Human Evidence Status: Most compelling data is Tier 2—mechanistically sound animal and in-vitro evidence with minimal or zero human RCT confirmation. The exception is skin/vascular effects, where human dosing studies explicitly demonstrate measurable facial flushing and blood flow increases. No human RCTs demonstrate fat loss, muscle growth, or cognitive enhancement from PACAP-38 supplementation.

Standard Protocol

Route Selection

Injectable (Subcutaneous or Intramuscular)

• Dose: 1–4 mcg/kg per administration (approximately 75–300 mcg for a 75 kg individual)
• Frequency: 2–3 times per week
• Onset: 5–15 minutes
• Duration: Effects typically resolve within 30–90 minutes (acute vasodilation); downstream signaling persists longer

Nasal (Intranasal)

• Dose: 100–300 mcg per nostril (200–600 mcg total per administration)
• Frequency: Once daily or every other day
• Onset: 10–20 minutes
• Duration: Similar to injection but with potentially slower systemic absorption

Route Recommendation: Injectable is more predictable for research and dosing consistency. Nasal administration offers convenience but absorption variability and local mucosal effects must be considered.

Baseline Cycle Structure

Duration: 8–12 weeks on, 4–6 weeks off

Rationale:

• Acute tolerance may develop to cardiovascular effects (flushing, hypotension) within 2–3 weeks
• Receptor desensitization to chronic cAMP elevation is a known pharmacological phenomenon with peptides
• Off-cycle periods allow hypothalamic-pituitary-adrenal (HPA) axis recalibration and receptor sensitization recovery
• Longer on-cycle (10–12 weeks) reserved for neuroprotection/recovery goals; shorter (8 weeks) acceptable for exploration or if side effects become problematic

Dose Escalation Protocol

Week 1–2: Start at 100 mcg (injection) or 200 mcg nasal, 2× per week

• Assess tolerance to flushing, cardiovascular effects, and headache
• Most common side effect: facial flushing and cutaneous vasodilation within minutes

Week 3–4: Increase to 150–200 mcg (injection) or 300 mcg nasal, 2–3× per week

• If well-tolerated, proceed; if flushing/hypotension is severe, maintain lower dose or reduce frequency

Week 5+: Move to 200–300 mcg (injection) or 300–600 mcg nasal at target frequency

• Maintenance phase: hold this dose for 6–10 weeks

Dose Ceiling: Do not exceed 300 mcg per injection or 600 mcg nasal (300 mcg per nostril × 2) per administration in standard protocols. Higher doses amplify cardiovascular stress without clear additional benefit.

Goal-Specific Protocols

Neuroprotection & Recovery (Injury, Nerve Damage, Post-Surgery)

Cycle: 10–12 weeks on, 4 weeks off

Dosing:

• Week 1–2: 100–150 mcg injection, 2× per week
• Week 3–4: 150–200 mcg injection, 2× per week
• Week 5–12: 200–250 mcg injection, 2–3× per week (3× if acute injury/post-surgery)

Rationale: Animal studies show PACAP accelerates nerve regeneration and myelin formation. Facial nerve injury models demonstrated 1-week acceleration in compound muscle action potential recovery. Higher frequency (3× weekly) justifiable in acute post-injury windows.

Stacking: Consider with BPC-157 (nerve regeneration synergy) at 250 mcg daily injection, separate site from PACAP.

Timeline to Assess: 6–8 weeks; objective markers (nerve conduction studies, functional recovery milestones) preferred over subjective reports.

Cognitive Support & Neuroprotection (Healthy Aging, Neurodegenerative Prevention)

Cycle: 10 weeks on, 5 weeks off, repeat

Dosing:

• Weeks 1–2: 100 mcg injection, 2× per week
• Weeks 3–10: 150–200 mcg injection, 2× per week

Rationale: BDNF upregulation, apoptosis inhibition, and ischemia-reperfusion protection are robust in animal models. Chronic, consistent dosing preferred over high-frequency acute dosing.

Stacking: Combine with cerebrolysin (10 mL IM/IV, 2–3× weekly) or semax (500 mcg nasal, once daily) for additive neuroprotection. Space nasal applications if using both PACAP and semax nasally (alternate nostrils or different times of day).

Monitoring: Cognitive testing (NIH Toolbox, MMSE if available) at baseline and week 10.

Metabolic Support & Fat Loss (Theoretical)

Cycle: 8 weeks on, 4 weeks off

Dosing:

• Weeks 1–2: 100 mcg injection, 2× per week
• Weeks 3–8: 150–200 mcg injection, 3× per week (satiety and energy expenditure mechanistically require consistent signaling)

Critical Caveat: No human evidence demonstrates fat loss. Animal data shows PACAP signaling in ventromedial hypothalamus and POMC neurons modulates appetite and thermogenesis, but human translocation is unproven. Use only as adjunct to diet and exercise.

Stacking:

• GLP-1 agonists (semaglutide, tirzepatide): Strong mechanistic overlap on appetite; consider lower PACAP frequency (2× weekly) to avoid over-suppression
• TB-500: 2 mg IM 2× weekly for metabolic effects (separate from PACAP injection sites)

Monitoring: Waist circumference, DEXA or InBody scan at baseline, week 4, week 8. Body weight alone is insufficient.

Mood, Stress Resilience & HPA Support

Cycle: 10 weeks on, 6 weeks off

Dosing:

• Weeks 1–3: 100–150 mcg injection, 2× per week
• Weeks 4–10: 150–200 mcg injection, 2× per week

Rationale: Mechanistic evidence for HPA axis modulation and PAC1 antagonism in animal stress models is compelling. However, human RCTs are absent. PAC1 receptor gene variants (ADCYAP1R1) associate with PTSD risk, suggesting individual pharmacogenetic variability.

Caution: PACAP also triggers flushing and cardiovascular activation acutely—paradoxically anxiety-inducing for some users. Start conservatively; monitor mood in first 2 weeks.

Stacking:

• Semax (500 mcg nasal, once daily): Complementary stress-response modulation
• Selank (500 mcg nasal, 2–3× weekly): Anxiolytic peptide without PACAP's vasodilatory profile

Monitoring: Perceived stress scale (PSS), salivary cortisol or 24-hour urine free cortisol at baseline and week 8.

Joint Health & Cartilage Support

Cycle: 12 weeks on, 6 weeks off

Dosing:

• Weeks 1–3: 100 mcg injection, 2× per week
• Weeks 4–12: 150–200 mcg injection, 3× per week (chronic joint disease may benefit from higher frequency)

Rationale: Synovial PACAP concentrations are lower in osteoarthritis patients and correlate with pain and radiographic severity. Animal models show chondroprotection. Mechanism likely involves anti-inflammatory and anabolic effects on synovial cells.

Local Administration Consideration: Some users inject directly into affected joints (intra-articular), but systemic circulation may be sufficient. Intra-articular dosing requires sterile technique and physician supervision.

Stacking:

• BPC-157 (250 mcg IM 2× weekly): Synergistic cartilage and joint protection
• Collagen peptides (10–20 g daily oral): Substrate support
• Hyaluronic acid (oral or IA): Structural joint support

Monitoring: Numeric pain rating scale (NRS), joint circumference, functional tests (6-minute walk, stair climb) at baseline, weeks 4, 8, 12.

How to Administer: Step-by-Step

Injectable Protocol (Subcutaneous Injection)

Equipment Needed:

• Sterile 1 mL insulin syringe (28–31 gauge) or 3 mL syringe with 25–27 gauge needle
• 70% isopropyl alcohol wipes
• Sharps disposal container
• Sterile gauze

Reconstitution (if lyophilized):

1. Determine total volume: use bacteriostatic water (0.9% sodium chloride with 0.9% benzyl alcohol) at 0.1–0.2 mL per 100 mcg PACAP desired
2. Draw bacteriostatic water into syringe
3. Inject into PACAP vial slowly; do not shake vigorously (may denature)
4. Let sit 2–3 minutes; gently swirl to dissolve
5. Final concentration should be ~1000 mcg/mL (adjust based on your vial's quantity)

Injection Steps:

1. Wash hands; alcohol-wipe injection site (abdomen, lateral thigh, or upper arm subcutaneous fat)
2. Allow alcohol to dry (2–5 seconds)
3. Pinch skin fold; insert needle at 45–90° angle into subcutaneous fat
4. Depress plunger slowly over 3–5 seconds
5. Withdraw needle; apply pressure with gauze for 10–15 seconds
6. Rotate injection sites to prevent lipohypertrophy (abdomen quadrants, thighs)

Storage (Reconstituted):

• Refrigerate at 2–8°C for up to 4 weeks
• Do not freeze reconstituted solution (degrades peptide)
• Lyophilized powder: store at room temperature, protected from light, for 12+ months

Intranasal Protocol

Equipment Needed:

• Nasal spray device or atomizer
• Sterile normal saline or bacteriostatic water for dilution

Administration Steps:

1. Clear nasal passages gently; tilt head slightly forward
2. Insert nozzle into one nostril; close opposite nostril
3. Depress atomizer/spray; coordinate with gentle inhalation
4. Repeat on opposite nostril if using 300 mcg per nostril dosing
5. Wait 30 seconds before tilting head back or blowing nose
6. Rinse spray device with sterile water after use

Concentration Guidance: 100–300 mcg per mL concentration in normal saline is standard for nasal delivery (achieves 100–300 mcg per 1–3 spray actuations).

Cycle Example: Week-by-Week Schedule

10-Week Neuroprotection/Recovery Cycle (Injectable)

Injection Sites: Week 1 (abdomen left), Week 2 (abdomen right), Week 3 (left thigh), Week 4 (right thigh), repeat rotation.

What to Expect: Timeline of Effects

Acute Phase (Minutes to Hours)

• 5–15 minutes post-injection: Facial flushing, warmth, facial/scalp erythema (dose-dependent; nearly universal at 200+ mcg)
• 10–20 minutes: Possible transient dizziness, mild hypotension (blood pressure may drop 10–20 mmHg), lightheadedness when standing
• 15–30 minutes: Potential headache or migraine-like sensations; reported in 10–20% of users
• 30–90 minutes: Flushing subsides; cardiovascular effects resolve

Mitigation: Inject in evening or when able to rest 30–60 minutes. Avoid driving during peak vasodilation window. Hydration and stable positioning reduce dizziness severity.

Subacute Phase (Days to Weeks)

• Week 1–2: Tolerance to flushing often develops; severity decreases even at same dose
• Week 2–3: If neuroprotection goal, no subjective symptoms expected; benefits are mechanistic (BDNF, anti-apoptosis)
• Week 3–4: Possible mild mood lift or sense of calm (if mood-related protocol); not guaranteed
• Week 4–6: Subjective "improvements" (energy, focus, joint comfort) are anecdotal; objective markers (nerve conduction, pain scores) preferred

Chronic Phase (Weeks 6–12)

• Weeks 6–10: Peak mechanistic window for neuroprotection, anti-inflammatory, and HPA modulation based on animal timeline studies
• Weeks 8–10: Receptor desensitization possible; flushing may partially return if tolerance waned
• Weeks 10–12: Continuation shows diminishing subjective returns in many users; reassess efficacy via objective testing

Common Protocol Mistakes

1. Escalating Dose Too Aggressively

Mistake: Jumping from 100 mcg to 300 mcg within days.
Problem: Excessive flushing, hypotension, potential syncope.
Fix: Follow 2-week steps; titrate by 50 mcg per adjustment.

2. Injecting Intravenously or Intramuscularly Unintentionally

Mistake: Penetrating deep muscle or blood vessel with subcutaneous technique.
Problem: IV administration (documented in migraine studies) causes rapid, severe systemic vasodilation and cardiovascular instability.
Fix: Pinch skin; inject at shallow angle into subcutaneous fat layer only.

3. Not Rotating Injection Sites

Mistake: Injecting same area repeatedly.
Problem: Lipohypertrophy (tissue fibrosis and fat nodules)